6,544 followers
New research: HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors: HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the… https://t.